101. Functional interpretation of metabolomics data as a new method for predicting long-term side effects: treatment of atopic dermatitis in infants.
- Author
-
Lee SJ, Woo SI, Ahn SH, Lim DK, Hong JY, Park JH, Lim J, Kim MK, and Kwon SW
- Subjects
- Anti-Inflammatory Agents, Non-Steroidal adverse effects, Desonide adverse effects, Double-Blind Method, Female, Humans, Infant, Male, Predictive Value of Tests, Skin Cream adverse effects, Tacrolimus administration & dosage, Tacrolimus adverse effects, Time Factors, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Dermatitis, Atopic drug therapy, Dermatitis, Atopic urine, Desonide administration & dosage, Metabolomics, Skin Cream administration & dosage, Tacrolimus analogs & derivatives
- Abstract
Topical steroids are used for the treatment of primary atopic dermatitis (AD); however, their associated risk of serious complications is great due to the presence of vulnerable lesions in young children with AD. Topical calcineurin inhibitors (TCIs) are steroid-free, anti-inflammatory agents used for topical AD therapy. However, their use is prohibited in infants <2 years of age because of their carcinogenic potential. We conducted a randomized, double-blind trial to evaluate the efficacy of TCIs as a secondary AD treatment for children <2 years of age by comparing 1% pimecrolimus cream with 0.05% desonide cream. We performed urinary metabolomics to predict long-term side effects. The 1% pimecrolimus cream displayed similar efficacy and exceptional safety compared with the 0.05% desonide cream. Metabolomics-based long-term toxicity tests effectively predicted long-term side effects using short-term clinical models. This applicable method for the functional interpretation of metabolomics data sets the foundation for future studies involving the prediction of the toxicity and systemic reactions caused by long-term medication administration.
- Published
- 2014
- Full Text
- View/download PDF